Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company’s current shareholders. The investigation seeks to determine whether...
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
3 Profitable Stocks That Fall Short
Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal’s growth profile into the 2030s ...
1 Healthcare Stock Worth Your Attention and 2 We Ignore
5 Insightful Analyst Questions From Amneal’s Q2 Earnings Call
AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance
Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%
– Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million ; Adjusted Diluted EPS of...